CathVision has secured US$7.2 million in funding from existing investors to help advance commercial operations driving adoption of the ECGenius system, the company’s EP recording technology.
Funding will also support the continued development of artificial intelligence-powered analytic modules to provide electrophysiologists with unprecedented levels of automated analysis during cardiac ablation procedures.
“Our investors have witnessed the evolution of our company and technology in recent years,” said Mads Matthiesen, CEO, CathVision. “Reinvesting in the company demonstrates confidence in our innovation, ongoing development, and ability to advance adoption of the ECGenius system throughout the USA as we focus on empowering physicians to diagnose, characterise, and treat cardiac arrhythmias more effectively. We are expanding our sales team, building our US presence, and furthering the development of analytic modules.”
The ECGenius system includes a proprietary hardware amplifier capable of acquiring high-fidelity, low-noise cardiac electrograms, CathVision details in a press release. The ECGenius system received US Food and Drug Administration (FDA) 510(k) clearance in May and is currently available in limited market release.
“Cardiac ablation is one of the fastest growing markets in healthcare; treatment efficiency and efficacy must improve for physicians to deliver the best possible care for patients with atrial fibrillation and other cardiac arrhythmias,” said Matthieu Bocquet, founding partner, Lumine Capital. “CathVision’s modern and precise EP recording technology brings more clarity to physicians by delivering clear signals that can be accurately interpreted. This is a necessary step to improve treatment outcomes.”